ABSTRACT
It has been shown that in patients with acute pyelonephritis a spontaneous production of the interleukin IL-1 remains unchanged, while that stimulated with the aid of LPS is significantly below the norm. A spontaneous secretion of IL-2 in patients with chronic pyelonephritis has also been found unchanged, whereas in acute pyelonephritis this same parameter tends to rise above the level recordable in healthy donors. The production of this lymphokine stimulated with the aid of PhHA is significantly lower both in acute and chronic pyelonephritis. The level of cells carrying receptors to IL-2 is appreciably above the norm in patients with acute pyelonephritis, whereas in those presenting with the chronic process this parameter does not differ from that in the control group. The data obtained suggest distinctive features in the interleukin link of immunity (IL-1, IL-1, IL-2P) in patients with pyelonephritis.
Subject(s)
Interleukin-1/blood , Interleukin-2/blood , Leukocytes, Mononuclear/immunology , Pyelonephritis/immunology , Receptors, Interleukin-2/blood , Acute Disease , Cells, Cultured , Chronic Disease , Humans , Leukocyte CountABSTRACT
A many as 20 patients with acute purulent pyelonephritis were studied for clinical and immunological effects of leukinferone. The above patients were convalescent earlier than control subjects. There were instances where clinical status was not accompanied by shifts in immunity. However, on an average in the group, such parameters as level of lymphocytes, amounts of B-cells, Igs G, A, T-helpers, and Tx/Tc ratio were found to be increased as was activity of EK-cells. Stimulating effects of leukinferone were particularly pronounced in those patients with decreased values for immunological status. A conclusion is reached to the effect that patients with acute pyelonephritis may benefit from those treatments involving the use of the above drug preparation.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Cytokines/therapeutic use , Interferon Type I/therapeutic use , Pyelonephritis/therapy , Acute Disease , Antibody Formation/drug effects , Combined Modality Therapy , Drug Combinations , Drug Evaluation , Female , Humans , Immunity, Cellular/drug effects , Male , Phagocytosis/drug effects , Postoperative Care , Pyelonephritis/immunologyABSTRACT
Results were studied of use of T-activin in those clinical settings related to acute inflammatory diseases of the kidneys. There was a positive clinical effect from this preparation in all twenty-eight patients with acute purulent pyelonephritis, accompanied by readjustments in the patients' immune system. A rise to the norm was found to occur in T-helper counts, and accordingly, immunoregulatory index, NK-cell activity, blood microbocydic activity. The in vitro investigations done suggested the need for individual testing of immunocompetent cells of the patient to optimize the therapy.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Peptides/therapeutic use , Pyelonephritis/drug therapy , Thymus Extracts/therapeutic use , Acute Disease , Antibody Formation/drug effects , Combined Modality Therapy , Humans , Immunity, Cellular/drug effects , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Lymphocyte Count/drug effects , Pyelonephritis/immunology , T-Lymphocytes/drug effects , T-Lymphocytes/immunologyABSTRACT
The effect of leukinferon (LKF) administration to 20 patients with acute renal inflammation was evaluated versus the effect of basic therapy given to 19 matched patients. A short course of LKF (3 injections) promoted more rapid discontinuation of the fever, recovery of satisfactory general condition, healing of postoperative wounds. Immunologically, the test subjects exhibited a rise in the previously low levels of lymphocytes, B-cells, T-helpers, IgA and IgG. The proportion of T-lymphocyte subpopulations improved and the activity of EC-cells enhanced. It is thought valid to use LKF in acute renal inflammation and surgical urological affections.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Cytokines/therapeutic use , Interferon Type I/therapeutic use , Pyelonephritis/immunology , Pyelonephritis/therapy , Acute Disease , Antibody Formation/drug effects , Combined Modality Therapy , Drug Combinations , Drug Evaluation , Female , Humans , Immunity, Cellular/drug effects , Male , Postoperative CareABSTRACT
The paper presents evidence on dysfunction of natural killer cells and abnormal proliferative response of peripheral blood mononuclears to T- and B-cell mitogens (PHA, Phytolacca) in patients at varying stages of acute pyelonephritis. A number of immunomodulators (recombinant alpha 2-interferon, IL-2 and tactivin) produce different effects on natural killer activity and lymphocyte blast transformation in healthy donors and pyelonephritis patients. Immunotropic effects of immunopeptides depend on the drug dose, the response of various subpopulations of the immunocompetent cells being individual. It is suggested that immune system, natural killer activity in particular, plays an important part in pathogenesis of acute pyelonephritis. In vitro experiments demonstrate that there can be a positive clinical response to tactivin and recombinant alpha 2-interferon administered in doses activating the function of certain immunocompetent cells.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Pyelonephritis/immunology , Acute Disease , Adolescent , Adult , Aged , Cell Line , Cells, Cultured/drug effects , Cells, Cultured/immunology , Cytotoxicity Tests, Immunologic , Dose-Response Relationship, Immunologic , Female , Humans , Immunity, Cellular/drug effects , Immunity, Cellular/immunology , Male , Middle Aged , Pyelonephritis/drug therapyABSTRACT
The quantitative and functional state of different populations of immunocompetent cells was studied in 45 patients with acute serous and 46 patients with acute purulent pyelonephritis. An imbalance has been found in the system of regulatory cells, activation of phagocytosis with reduction of its reserve capacities, disorders of IL-producing capacity of mononuclears and suppression of the functional activity of NK cells.
